Literature DB >> 23364630

Repeated analysis of estimated insulin resistance using the HOMAIR index in nondiabetic patients on peritoneal dialysis and its relationship with cardiovascular disease and mortality.

Rafael Sánchez-Villanueva1, Patricia Estrada, Gloria del Peso, Cristina Grande, Juan J Díez, Pedro Iglesias, Elena González, Ana Aguilar-Rodríguez, Rafael Selgas, M Auxiliadora Bajo.   

Abstract

Terminal chronic renal failure patients show early insulin resistance (IR), characterised by alterations in the hydrocarbon metabolism and hyperinsulinaemia generally associated with dyslipidaemia and a proinflammatory condition. Cardiovascular disease (CVD) is the main cause of mortality in patients on dialysis. There is a strong association between IR, hyperinsulinism and CV disease. The objective of this study was to evaluate the effect of peritoneal dialysis (PD) on IR and its effects on the subsequent CVD morbidity and mortality in nondiabetic uraemic patients. It involved 69 nondiabetic patients on PD, 35 incident patients (≤ 3 months on PD) and 34 prevalent patients (>3 months on PD), with 2 estimated insulin resistance measurements 12 months apart using the insulin resistance index (HOMAIR). The mean HOMAIR value in incident patients was 1.8 ± 1.3 and 2.2 ± 2.1 at baseline situation and at 12 months respectively (not significant [NS]). In prevalent patients these values were 2.3 ± 1.3 and 2.5 ± 2.2 (NS). In our study, the mean glucose, insulin and IR concentrations measured by the HOMAIR and QUICKI indexes (the latter being a quantitative control for insulin sensitivity control) were similar at baseline situation and the following year, in both incident and prevalent patients. We did not find any significant differences in relation to CVD comorbidity, ischaemic heart disease, heart failure or cerebrovascular or peripheral comorbidity neither in the HOMAIR index or insulin levels. To conclude, nondiabetic patients on PD do not display a significant increase in HOMAIR levels and this remains the case over time when on dialysis. This, in turn, suggests that PD is not an IR risk factor. The fact that the IR indexes are not associated with CVD morbidity or mortality seems to suggest that this is a less significant factor in the field of PD.

Entities:  

Mesh:

Year:  2013        PMID: 23364630     DOI: 10.3265/Nefrologia.pre2012.Nov.11430

Source DB:  PubMed          Journal:  Nefrologia        ISSN: 0211-6995            Impact factor:   2.033


  4 in total

1.  Insulin Resistance in Nondiabetic Peritoneal Dialysis Patients: Associations with Body Composition, Peritoneal Transport, and Peritoneal Glucose Absorption.

Authors:  Ana Paula Bernardo; Jose C Oliveira; Olivia Santos; Maria J Carvalho; Antonio Cabrita; Anabela Rodrigues
Journal:  Clin J Am Soc Nephrol       Date:  2015-10-27       Impact factor: 8.237

2.  Fibroblast Growth Factor 21 (FGF-21) in Peritoneal Dialysis Patients: Natural History and Metabolic Implications.

Authors:  Elena González; Juan J Díez; M Auxiliadora Bajo; Gloria del Peso; Cristina Grande; Olaia Rodríguez; Mariana Díaz-Almirón; Pedro Iglesias; Rafael Selgas
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

3.  Metabolic clustering of risk factors: evaluation of Triglyceride-glucose index (TyG index) for evaluation of insulin resistance.

Authors:  Sikandar Hayat Khan; Farah Sobia; Najmusaqib Khan Niazi; Syed Mohsin Manzoor; Nadeem Fazal; Fowad Ahmad
Journal:  Diabetol Metab Syndr       Date:  2018-10-05       Impact factor: 3.320

Review 4.  Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis.

Authors:  Mark Lambie; Mario Bonomini; Simon J Davies; Domenico Accili; Arduino Arduini; Victor Zammit
Journal:  Trends Endocrinol Metab       Date:  2021-07-12       Impact factor: 10.586

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.